TABLE 1.
Characteristics of New York City residents who tested positive for SARS‐CoV‐2 infection during periods of Omicron (January 2022) and Delta (August–November 2021) variant predominance
| Diagnosis of SARS‐CoV‐2 infection | Hospitalized | Died | ||||
|---|---|---|---|---|---|---|
| Omicron | Delta | Omicron | Delta | Omicron | Delta | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Total | 488,053 | 158,799 | 16,025 | 8268 | 2696 | 1196 |
| Gender | ||||||
| Female | 268,378 (55.0%) | 83,542 (52.6%) | 8492 (53.0%) | 4249 (51.4%) | 1255 (46.6%) | 561 (46.9%) |
| Male | 216,505 (44.4%) | 74,837 (47.1%) | 7526 (47.0%) | 4017 (48.6%) | 1441 (53.4%) | 635 (53.1%) |
| Unknown or missing | 3170 (0.6%) | 420 (0.3%) | 7 (0.0%) | 2 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Age group (years) | ||||||
| <10 | 61,075 (12.5%) | 17,007 (10.7%) | 737 (4.6%) | 277 (3.4%) | 2 (0.1%) | 0 (0.0%) |
| 10–19 | 65,319 (13.4%) | 18,946 (11.9%) | 423 (2.6%) | 219 (2.6%) | 1 (0.0%) | 1 (0.1%) |
| 20–29 | 75,672 (15.5%) | 34,207 (21.5%) | 1141 (7.1%) | 690 (8.3%) | 11 (0.4%) | 5 (0.4%) |
| 30–39 | 81,844 (16.8%) | 33,104 (20.8%) | 1501 (9.4%) | 1060 (12.8%) | 42 (1.6%) | 32 (2.7%) |
| 40–49 | 66,242 (13.6%) | 19,879 (12.5%) | 1246 (7.8%) | 928 (11.2%) | 84 (3.1%) | 67 (5.6%) |
| 50–59 | 60,271 (12.3%) | 15,384 (9.7%) | 1965 (12.3%) | 1271 (15.4%) | 176 (6.5%) | 159 (13.3%) |
| 60–69 | 43,038 (8.8%) | 11,154 (7.0%) | 2640 (16.5%) | 1407 (17.0%) | 432 (16.0%) | 222 (18.6%) |
| 70–79 | 21,743 (4.5%) | 5952 (3.7%) | 2801 (17.5%) | 1235 (14.9%) | 650 (24.1%) | 309 (25.8%) |
| 80–89 | 9546 (2.0%) | 2447 (1.5%) | 2465 (15.4%) | 851 (10.3%) | 746 (27.7%) | 235 (19.6%) |
| ≥90 | 3165 (0.6%) | 688 (0.4%) | 1106 (6.9%) | 330 (4.0%) | 552 (20.5%) | 166 (13.9%) |
| Unknown or missing | 138 (0.0%) | 31 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Race/ethnicity | ||||||
| Non‐Hispanic Asian/Pacific Islander | 67,981 (13.9%) | 12,919 (8.1%) | 1236 (7.7%) | 510 (6.2%) | 267 (9.9%) | 83 (6.9%) |
| Non‐Hispanic Black/African American | 64,382 (13.2%) | 26,961 (17.0%) | 4624 (28.9%) | 2436 (29.5%) | 769 (28.5%) | 329 (27.5%) |
| Hispanic/Latino | 128,899 (26.4%) | 33,446 (21.1%) | 4592 (28.7%) | 2253 (27.2%) | 604 (22.4%) | 267 (22.3%) |
| Non‐Hispanic White | 98,484 (20.2%) | 51,385 (32.4%) | 4169 (26.0%) | 2288 (27.7%) | 924 (34.3%) | 425 (35.5%) |
| Non‐Hispanic Other | 3139 (0.6%) | 2940 (1.9%) | 202 (1.3%) | 250 (3.0%) | 68 (2.5%) | 55 (4.6%) |
| Unknown | 125,168 (25.6%) | 31,148 (19.6%) | 1202 (7.5%) | 531 (6.4%) | 64 (2.4%) | 37 (3.1%) |
| Congregate setting resident a | ||||||
| Yes | 5447 (1.1%) | 1144 (0.7%) | 883 (5.5%) | 326 (3.9%) | 476 (17.7%) | 150 (12.5%) |
| No | 458,578 (94.0%) | 156,365 (98.5%) | 14,671 (91.6%) | 7895 (95.5%) | 2183 (81.0%) | 1046 (87.5%) |
| Unknown or missing | 24,028 (4.9%) | 1290 (0.8%) | 471 (2.9%) | 47 (0.6%) | 37 (1.4%) | 0 (0.0%) |
| Census tract‐based poverty level b | ||||||
| Low | 133,738 (27.4%) | 52,927 (33.3%) | 3514 (21.9%) | 2154 (26.1%) | 701 (26.0%) | 369 (30.9%) |
| Medium | 150,231 (30.8%) | 48,374 (30.5%) | 4673 (29.2%) | 2451 (29.6%) | 908 (33.7%) | 366 (30.6%) |
| High | 90,218 (18.5%) | 27,329 (17.2%) | 3333 (20.8%) | 1675 (20.3%) | 508 (18.8%) | 217 (18.1%) |
| Very high | 84,124 (17.2%) | 25,877 (16.3%) | 3728 (23.3%) | 1776 (21.5%) | 491 (18.2%) | 217 (18.1%) |
| Unknown or missing | 29,742 (6.1%) | 4292 (2.7%) | 777 (4.8%) | 212 (2.6%) | 88 (3.3%) | 27 (2.3%) |
| Prior COVID‐19 diagnosis | ||||||
| Yes | 42,115 (8.6%) | 6057 (3.8%) | 1118 (7.0%) | 282 (3.4%) | 106 (3.9%) | 41 (3.4%) |
| No | 445,938 (91.4%) | 152,742 (96.2%) | 14,907 (93.0%) | 7986 (96.6%) | 2590 (96.1%) | 1155 (96.6%) |
| Days since prior diagnosis | ||||||
| 91–180 | 1052 (2.5%) | 776 (12.8%) | 23 (2.1%) | 72 (25.5%) | 2 (1.9%) | 16 (39.0%) |
| 180–269 | 2485 (5.9%) | 1762 (29.1%) | 64 (5.7%) | 115 (40.8%) | 5 (4.7%) | 15 (36.6%) |
| 270–359 | 15,581 (37.0%) | 1211 (20.0%) | 369 (33.0%) | 35 (12.4%) | 37 (34.9%) | 2 (4.9%) |
| 360–449 | 12,268 (29.1%) | 1326 (21.9%) | 281 (25.1%) | 18 (6.4%) | 20 (18.9%) | 2 (4.9%) |
| ≥450 | 10,729 (25.5%) | 972 (16.0%) | 381 (34.1%) | 42 (14.9%) | 42 (39.6%) | 6 (14.6%) |
| Number of COVID‐19 vaccine doses c | ||||||
| 0 | 190,611 (39.1%) | 102,939 (64.8%) | 7935 (49.5%) | 6139 (74.3%) | 1413 (52.4%) | 850 (71.1%) |
| 1 | 27,574 (5.6%) | 4417 (2.8%) | 902 (5.6%) | 252 (3.0%) | 121 (4.5%) | 40 (3.3%) |
| 2 | 200,284 (41.0%) | 50,897 (32.1%) | 5558 (34.7%) | 1849 (22.4%) | 865 (32.1%) | 301 (25.2%) |
| 3 | 69,584 (14.3%) | 546 (0.3%) | 1630 (10.2%) | 28 (0.3%) | 297 (11.0%) | 5 (0.4%) |
| Days since 14‐day period had passed after most recent COVID‐19 vaccine dose | ||||||
| <90 | 116,427 (39.1%) | 9922 (17.8%) | 2498 (30.9%) | 422 (19.8%) | 373 (29.1%) | 55 (15.9%) |
| 90–179 | 55,478 (18.7%) | 27,350 (49.0%) | 1572 (19.4%) | 961 (45.1%) | 213 (16.6%) | 159 (46.0%) |
| 180–269 | 94,678 (31.8%) | 17,630 (31.6%) | 2544 (31.4%) | 697 (32.7%) | 401 (31.3%) | 127 (36.7%) |
| ≥270 | 28,868 (9.7%) | 741 (1.3%) | 1437 (17.8%) | 34 (1.6%) | 296 (23.1%) | 4 (1.2%) |
a
Congregate settings defined as having a residential address as of diagnosis of a nursing home, jail, or prison.
b
Low poverty defined as <10% of residents below the federal poverty level, medium as 10% to <20%, high as 20 to <30%, and very high as ≥30%.
c
A second dose of the BNT162b2 vaccine was considered valid if it was administered ≥17 days (3 weeks minus 4‐day grace period) after a first dose of BNT162b2 or ≥28 days after a first dose of mRNA‐1273. A second dose of the mRNA‐1273 vaccine was considered valid if it was administered ≥24 days (4 weeks minus a 4‐day grace period) after a first dose of mRNA‐1273 or ≥28 days after a first dose of BNT162b2. A third dose was considered valid if it was administered ≥150 days after a second dose of vaccine from either manufacturer.